Terms: = Ovarian cancer AND EPS15, AF-1P, 2060, ENSG00000085832, P42566, MLLT5, AF1P
16 results:
1. Sedentary behaviour in relation to ovarian cancer risk: a systematic review and meta-analysis.
Biller VS; Leitzmann MF; Sedlmeier AM; Berger FF; Ortmann O; Jochem C
Eur J Epidemiol; 2021 Aug; 36(8):769-780. PubMed ID: 33492550
[TBL] [Abstract] [Full Text] [Related]
2. Chemoresistance in ovarian cancer: Prospects for New Drugs.
Tendulkar S; Dodamani S
Anticancer Agents Med Chem; 2021; 21(6):668-678. PubMed ID: 32900355
[TBL] [Abstract] [Full Text] [Related]
3. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and ovarian cancer.
Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
[TBL] [Abstract] [Full Text] [Related]
4. [The clinicopathological features and risk factors of recurrence in patients with mucinous borderline ovarian tumors].
Sun L; Song Y; Li N; Yuan GW; Sun YC; Li N; Ma SK; Zhang X; Wu LY
Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):589-594. PubMed ID: 28835081
[No Abstract] [Full Text] [Related]
5. Comparative analysis of tumor spheroid generation techniques for differential in vitro drug toxicity.
Raghavan S; Mehta P; Horst EN; Ward MR; Rowley KR; Mehta G
Oncotarget; 2016 Mar; 7(13):16948-61. PubMed ID: 26918944
[TBL] [Abstract] [Full Text] [Related]
6. Role of EHD2 in migration and invasion of human breast cancer cells.
Yang X; Ren H; Yao L; Chen X; He A
Tumour Biol; 2015 May; 36(5):3717-26. PubMed ID: 25557791
[TBL] [Abstract] [Full Text] [Related]
7. A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Penson RT; Moore KM; Fleming GF; Braly P; Schimp V; Nguyen H; Matulonis UA; Banerjee S; Haluska P; Gore M; Bodurka DC; Hozak RR; Joshi A; Xu Y; Schwartz JD; McGuire WP
Gynecol Oncol; 2014 Sep; 134(3):478-85. PubMed ID: 25016924
[TBL] [Abstract] [Full Text] [Related]
8. A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer.
Xiao K; Luo J; Fowler WL; Li Y; Lee JS; Xing L; Cheng RH; Wang L; Lam KS
Biomaterials; 2009 Oct; 30(30):6006-16. PubMed ID: 19660809
[TBL] [Abstract] [Full Text] [Related]
9. [Preventive surgical prcedures for inherited risk of breast cancer].
Menke-Pluymers MB; Seynaeve C; van Geel AN; Klijn JG; Meijers-Heijboer EJ; Eggermont AM
Ned Tijdschr Geneeskd; 2005 Nov; 149(48):2663-7. PubMed ID: 16358615
[TBL] [Abstract] [Full Text] [Related]
10. DNA ploidy and S phase fraction of breast and ovarian tumor cells treated with a natural anthracycline analog (aloin).
Esmat AY; El-Gerzawy SM; Rafaat A
Cancer Biol Ther; 2005 Jan; 4(1):108-12. PubMed ID: 15662120
[TBL] [Abstract] [Full Text] [Related]
11. Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer.
Galper S; Gelman R; Recht A; Silver B; Kohli A; Wong JS; Van Buren T; Baldini EH; Harris JR
Int J Radiat Oncol Biol Phys; 2002 Feb; 52(2):406-14. PubMed ID: 11872286
[TBL] [Abstract] [Full Text] [Related]
12. Expression of glutathione S-transferase pi (GST-pi) in human malignant ovarian tumors.
Satoh T; Nishida M; Tsunoda H; Kubo T
Eur J Obstet Gynecol Reprod Biol; 2001 Jun; 96(2):202-8. PubMed ID: 11384808
[TBL] [Abstract] [Full Text] [Related]
13. Growth factors interact with estradiol and gonadotropins in the regulation of ovarian cancer cell growth and growth factor receptors.
Wimalasena J; Meehan D; Dostal R; Foster JS; Cameron M; Smith M
Oncol Res; 1993; 5(8):325-37. PubMed ID: 8012064
[TBL] [Abstract] [Full Text] [Related]
14. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma.
Fanning J; Bennett TZ; Hilgers RD
Obstet Gynecol; 1992 Dec; 80(6):954-60. PubMed ID: 1333066
[TBL] [Abstract] [Full Text] [Related]
15. Characterization of inactive renin ("prorenin") from renin-secreting tumors of nonrenal origin. Similarity to inactive renin from kidney and normal plasma.
Atlas SA; Hesson TE; Sealey JE; Dharmgrongartama B; Laragh JH; Ruddy MC; Aurell M
J Clin Invest; 1984 Feb; 73(2):437-47. PubMed ID: 6365974
[TBL] [Abstract] [Full Text] [Related]
16. A testosterone-secreting, gonadotropin-responsive pure thecoma and polycystic ovarian disease.
Givens JR; Andersen RN; Wiser WL; Donelson AJ; Coleman SA
J Clin Endocrinol Metab; 1975 Nov; 41(5):845-53. PubMed ID: 171277
[TBL] [Abstract] [Full Text] [Related]
